These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
236 related articles for article (PubMed ID: 31939424)
1. Decitabine: An effective and safe treatment for myelodysplastic syndrome and acute myeloid leukemia. Feng X; Chen X; Nie S; Chang Y; Meng F; Zhou J; Mao C; Li T; Yan X; Huang J; Liu S; Gao Y; Xiao S J Cancer Res Ther; 2019; 15(7):1471-1476. PubMed ID: 31939424 [TBL] [Abstract][Full Text] [Related]
2. Comparison of Azacitidine and Decitabine in Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Network Meta-analysis. Liu W; Zhou Z; Chen L; Wang X Clin Lymphoma Myeloma Leuk; 2021 Jun; 21(6):e530-e544. PubMed ID: 33716056 [TBL] [Abstract][Full Text] [Related]
3. Low-dose decitabine plus venetoclax is safe and effective as post-transplant maintenance therapy for high-risk acute myeloid leukemia and myelodysplastic syndrome. Wei Y; Xiong X; Li X; Lu W; He X; Jin X; Sun R; Lyu H; Yuan T; Sun T; Zhao M Cancer Sci; 2021 Sep; 112(9):3636-3644. PubMed ID: 34185931 [TBL] [Abstract][Full Text] [Related]
4. Epigenetic priming with decitabine followed by low dose idarubicin and cytarabine in acute myeloid leukemia evolving from myelodysplastic syndromes and higher-risk myelodysplastic syndromes: a prospective multicenter single-arm trial. Zhou X; Mei C; Zhang J; Lu Y; Lan J; Lin S; Zhang Y; Kuang Y; Ren Y; Ma L; Wei J; Ye L; Xu W; Li K; Lu C; Jin J; Tong H Hematol Oncol; 2020 Oct; 38(4):531-540. PubMed ID: 32469434 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and toxicity of Decitabine in patients with acute myeloid leukemia (AML): A multicenter real-world experience. Filì C; Candoni A; Zannier ME; Olivieri J; Imbergamo S; Caizzi M; Nadali G; Di Bona E; Ermacora A; Gottardi M; Facchinelli D; Ciancia R; Lazzarotto D; Dubbini MV; Festini G; Gherlinzoni F; Michieli MG; Semenzato G; Fanin R Leuk Res; 2019 Jan; 76():33-38. PubMed ID: 30529681 [TBL] [Abstract][Full Text] [Related]
6. Decitabine in the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndromes, Which Combined with Complex Karyotype Respectively. Gao S; Li Z; Fu JH; Hu XH; Xu Y; Jin ZM; Tang XW; Han Y; Chen SN; Sun AN; Wu DP; Qiu HY Asian Pac J Cancer Prev; 2015; 16(15):6627-32. PubMed ID: 26434886 [TBL] [Abstract][Full Text] [Related]
7. Decitabine improves overall survival in myelodysplastic syndromes-RAEB patients aged ≥60 years and has lower toxicities: Comparison with low-dose chemotherapy. Ye L; Ren Y; Zhou X; Mei C; Xu W; Ma L; Luo Y; Hu C; Ye X; Wei J; Lou Y; Jin J; Tong H Blood Cells Mol Dis; 2019 Jul; 77():88-94. PubMed ID: 31005752 [TBL] [Abstract][Full Text] [Related]
8. TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes. Welch JS; Petti AA; Miller CA; Fronick CC; O'Laughlin M; Fulton RS; Wilson RK; Baty JD; Duncavage EJ; Tandon B; Lee YS; Wartman LD; Uy GL; Ghobadi A; Tomasson MH; Pusic I; Romee R; Fehniger TA; Stockerl-Goldstein KE; Vij R; Oh ST; Abboud CN; Cashen AF; Schroeder MA; Jacoby MA; Heath SE; Luber K; Janke MR; Hantel A; Khan N; Sukhanova MJ; Knoebel RW; Stock W; Graubert TA; Walter MJ; Westervelt P; Link DC; DiPersio JF; Ley TJ N Engl J Med; 2016 Nov; 375(21):2023-2036. PubMed ID: 27959731 [TBL] [Abstract][Full Text] [Related]
9. Outcomes of newly diagnosed acute myeloid leukemia with myelodysplasia related changes and elderly acute myeloid leukemia following decitabine therapy in combination with priming regimen. Lai B; Mu Q; Zhang Y; Chen Y; Yan X; Ouyang G Hematology; 2021 Dec; 26(1):751-757. PubMed ID: 34555298 [TBL] [Abstract][Full Text] [Related]
10. A favorable inductive remission rate for decitabine combined with chemotherapy as a first course in <60-year-old acute myeloid leukemia patients with myelodysplasia syndrome features. Liu F; Wang H; Liu J; Zhou Z; Zheng D; Huang B; Su C; Zou W; Xu D; Tong X; Li J Cancer Med; 2019 Sep; 8(11):5108-5115. PubMed ID: 31322840 [TBL] [Abstract][Full Text] [Related]
11. Lack of objective response of myelodysplastic syndromes and acute myeloid leukemia to decitabine after failure of azacitidine. Duong VH; Bhatnagar B; Zandberg DP; Vannorsdall EJ; Tidwell ML; Chen Q; Baer MR Leuk Lymphoma; 2015 Jun; 56(6):1718-22. PubMed ID: 25263320 [TBL] [Abstract][Full Text] [Related]
12. [Clinical observation of decitabine-treating patients with myelodysplastic syndrome and acute myeloid leukemia]. Yang H; Zhu HY; Jiang MM; Wang QS; Han XP; Huang WR; Jing Y; Wang SH; Zhang SS; Mei JH; Yu L Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Feb; 21(1):121-5. PubMed ID: 23484704 [TBL] [Abstract][Full Text] [Related]
13. [Efficacy and Safety of Decitabine Combined with Modified EIAG Regimen in the Treatment of Patients with Relapsed/Refractory Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome]. Mao JP; Xue LG; Zhu YX; Jia T; Wang Y; Miao L; Wei JF; Zhao LD Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Apr; 31(2):338-343. PubMed ID: 37096503 [TBL] [Abstract][Full Text] [Related]
14. Patterns of infectious complications in acute myeloid leukemia and myelodysplastic syndromes patients treated with 10-day decitabine regimen. Ali AM; Weisel D; Gao F; Uy GL; Cashen AF; Jacoby MA; Wartman LD; Ghobadi A; Pusic I; Romee R; Fehniger TA; Stockerl-Goldstein KE; Vij R; Oh ST; Abboud CN; Schroeder MA; Westervelt P; DiPersio JF; Welch JS Cancer Med; 2017 Dec; 6(12):2814-2821. PubMed ID: 29058375 [TBL] [Abstract][Full Text] [Related]
15. Randomized open-label phase II study of decitabine in patients with low- or intermediate-risk myelodysplastic syndromes. Garcia-Manero G; Jabbour E; Borthakur G; Faderl S; Estrov Z; Yang H; Maddipoti S; Godley LA; Gabrail N; Berdeja JG; Nadeem A; Kassalow L; Kantarjian H J Clin Oncol; 2013 Jul; 31(20):2548-53. PubMed ID: 23733767 [TBL] [Abstract][Full Text] [Related]
16. Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome. Kantarjian HM; O'Brien S; Shan J; Aribi A; Garcia-Manero G; Jabbour E; Ravandi F; Cortes J; Davisson J; Issa JP Cancer; 2007 Jan; 109(2):265-73. PubMed ID: 17133405 [TBL] [Abstract][Full Text] [Related]
17. Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience. Kantarjian HM; O'Brien S; Huang X; Garcia-Manero G; Ravandi F; Cortes J; Shan J; Davisson J; Bueso-Ramos CE; Issa JP Cancer; 2007 Mar; 109(6):1133-7. PubMed ID: 17315156 [TBL] [Abstract][Full Text] [Related]
18. Retrospective analysis of prognostic factors associated with response and overall survival by baseline marrow blast percentage in patients with myelodysplastic syndromes treated with decitabine. Jabbour E; Kantarjian H; O'Brien S; Kadia T; Malik A; Welch MA; Teng A; Cortes J; Ravandi F; Garcia-Manero G Clin Lymphoma Myeloma Leuk; 2013 Oct; 13(5):592-6. PubMed ID: 23790798 [TBL] [Abstract][Full Text] [Related]
19. Prognostic factors associated with disease progression and overall survival in patients with myelodysplastic syndromes treated with decitabine. Jabbour E; Garcia-Manero G; Ravandi F; Faderl S; O'Brien S; Fullmer A; Cortes JE; Wierda W; Kantarjian H Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):131-8. PubMed ID: 23260600 [TBL] [Abstract][Full Text] [Related]
20. [The clinical safety and efficacy of low dose subcutaneous decitabine in treating acute myeloid leukemia and intermediate- or higer-risk myelodysplastic syndromes in the elderly patients]. Ai H; Wei XD; Yin QS; Wang P; Mi RH; Yuan FF; Chen L; Song YP Zhonghua Nei Ke Za Zhi; 2017 Aug; 56(8):606-609. PubMed ID: 28789495 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]